Dominique Demonte, Head of the Brussels South Charleroi BioPark (Belgium) and Catherine Muller, Executive VP at 3Biotech, have signed a partnership agreement to accelerate the growth of biotech projects developed within the Biopark.
Founded and managed by Olivier Favre-Bulle, 3Biotech is now the reference for managing and steering biotechs' translational pre-clinical CMC (Chemistry Manufacturing and Control) phases.
Recognized by Bpifrance for its expertise in drug development, 3Biotech is strengthening its presence in Europe. The Biopark will be home to over 85 biotech players, representing 3,500 employees. The cluster has become a heavyweight in innovation, representing 20% of all European production capacity for cell and gene therapies.